The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 355:2598-2599 December 14, 2006 Number 24
NextNext

Heparin-Induced Thrombocytopenia

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Arepally, G. M.
To the Editor: Arepally and Ortel (Aug. 24 issue)1 review the role of bivalirudin as one of the therapeutic options in the management of heparin-induced thrombocytopenia. In Table 2 of their article, the activated clotting time is listed as a means of monitoring the anticoagulation profile of bivalirudin. There is no linear correlation between the standard activated clotting time and the plasma bivalirudin concentration.2,3 Several studies have shown that the standard activated clotting time does not provide an accurate measurement of the anticoagulation effect of bivalirudin, especially at large doses.3,4,5 However, there is a good linear relationship between the bivalirudin . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.